Top biotechnology stock pick from Guggenheim

Guggenheim has designated First Tracks Biotherapeutics (TRAX) as its top biotechnology stock pick, buoyed by promising Phase II celiac disease study results from argenx. The investment firm sees the recent positive data from argenx as reducing risk in TRAX's CD122 biology approach for celiac disease, lending confidence ahead of TRAX's own fourth quarter 2026 data readout.

Guggenheim's analysis considers four key factors: effect size, study powering, gluten challenge parameters, and expectations for TRAX. The firm estimates argenx's placebo-adjusted delta at 0.2 to 0.3, based on a p-value of 0.0176. TRAX's management is optimistic about their 30-patient study, which they believe is sufficiently powered to demonstrate statistically significant results for the Vh:Cd endpoint, despite the smaller sample size compared to argenx's 126-patient study.

The gluten challenge in TRAX's study involves administering 6 grams per day for two weeks, equivalent to about two slices of bread, which management deems sufficient to induce mucosal injury. Guggenheim outlines two potential scenarios for TRAX: a base case with statistically significant Vh:Cd results could propel the stock to trade between $2.5 billion and $3 billion, while an upside scenario with significant Vh:Cd results and a treatment difference greater than 0.3 could value the stock above $3 billion, implying a more potent anti-CD122 molecule than FB102, with further differentiation through a subcutaneous formulation.

TRAX is anticipated to release preliminary results from its Phase Ib celiac disease program in the fourth quarter of 2026. This positive data from argenx is Guggenheim's fourth successful celiac disease study across IL-15/CD122 programs, which they believe significantly reduces risk for ANB033 ahead of the upcoming readout.